Oncotarget

Meta-Analysis:

Prognostic role of the pre-treatment platelet-lymphocyte ratio in pancreatic cancer: a meta-analysis

Zheng-Shui Xu, Fa-Peng Zhang, Yin Zhang, Yong-Peng Ou-Yang, Xiao-Wen Yu, Wen-Long Wang, Wen-Ji Xu and Zhi-Qiang Luo _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:99003-99012. https://doi.org/10.18632/oncotarget.20871

Metrics: PDF 1482 views  |   HTML 2025 views  |   ?  


Abstract

Zheng-Shui Xu1,*, Fa-Peng Zhang2,*, Yin Zhang3, Yong-Peng Ou-Yang3, Xiao-Wen Yu3, Wen-Long Wang3, Wen-Ji Xu3 and Zhi-Qiang Luo3

1Department of General Surgery, GuangRen Hospital of Xi’an Jiaotong University, 710000, Xi’an, Shaanxi, China

2Department of General Surgery, The Second Affiliated Hospital of Sun Yat-Sen University, 510120, Guangzhou, Guangdong, China

3Department of General Surgery, The Second Affiliated Hospital of Nanchang University, 330006, Nanchang, Jiangxi, China

*These authors contributed equally to this study and share first authorship

Correspondence to:

Zhi-Qiang Luo, email: [email protected]

Wen-Ji Xu, email: [email protected]

Keywords: PLR, pancreatic cancer, overall survival, meta-analysis

Received: December 20, 2016     Accepted: September 03, 2017     Published: September 14, 2017

ABSTRACT

Background and Aims: Recently, the pre-treatment platelet-lymphocyte ratio (PLR), which is based on blood parameters, was accepted as a prognostic factor for patients with various cancers. Numerous studies have investigated the prognostic role of the PLR in pancreatic cancer; however, it remains unclear. Therefore, we conducted this meta-analysis to evaluate the relationship between the pre-treatment PLR and overall survival (OS) in pancreatic cancer.

Materials and Methods: We performed a systematic literature search of the PubMed, Embase and Web of Science databases for relevant studies that explored the prognostic role of the pre-treatment PLR in pancreatic cancer. The hazard ratios (HRs) and 95% confidence intervals (CIs) related to OS were pooled using a random effects model.

Results: Fourteen retrospective cohort studies involving 2,260 patients were included in this meta-analysis. Compared with low PLR, high PLR was a predictor of shorter OS (HR = 1.24, 95% CI: 1.10–1.39, I2 = 74%).

Conclusions: In this meta-analysis, high pre-treatment PLR was a bio-predictor of short OS in patients with pancreatic cancer, suggesting that PLR could be used to predict prognosis of patients with pancreatic cancer before treatment. However, additional well-designed and large-scale studies are necessary.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20871